118 related articles for article (PubMed ID: 31419676)
1. Design, synthesis, and anticancer activity of iridium(III) complex-peptide hybrids that contain hydrophobic acyl groups at the N-terminus of the peptide units.
Naito K; Yokoi K; Balachandran C; Hisamatsu Y; Aoki S
J Inorg Biochem; 2019 Oct; 199():110785. PubMed ID: 31419676
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of Amphiphilic and Luminescent Tris-Cyclometalated Iridium(III) Complexes Containing Cationic Peptides as Inducers and Detectors of Cell Death via a Calcium-Dependent Pathway.
Hisamatsu Y; Shibuya A; Suzuki N; Suzuki T; Abe R; Aoki S
Bioconjug Chem; 2015 May; 26(5):857-79. PubMed ID: 25875312
[TBL] [Abstract][Full Text] [Related]
3. Cationic Amphiphilic Tris-Cyclometalated Iridium(III) Complexes Induce Cancer Cell Death via Interaction with Ca
Hisamatsu Y; Suzuki N; Masum AA; Shibuya A; Abe R; Sato A; Tanuma SI; Aoki S
Bioconjug Chem; 2017 Feb; 28(2):507-523. PubMed ID: 28032992
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis.
Masum AA; Yokoi K; Hisamatsu Y; Naito K; Shashni B; Aoki S
Bioorg Med Chem; 2018 Sep; 26(17):4804-4816. PubMed ID: 30177492
[TBL] [Abstract][Full Text] [Related]
5. Cyclometalated Iridium(III) Complex-Cationic Peptide Hybrids Trigger Paraptosis in Cancer Cells via an Intracellular Ca
Balachandran C; Yokoi K; Naito K; Haribabu J; Tamura Y; Umezawa M; Tsuchiya K; Yoshihara T; Tobita S; Aoki S
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834120
[TBL] [Abstract][Full Text] [Related]
6. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
7. Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death.
Masum AA; Hisamatsu Y; Yokoi K; Aoki S
Bioinorg Chem Appl; 2018; 2018():7578965. PubMed ID: 30154833
[TBL] [Abstract][Full Text] [Related]
8. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway.
Tang B; Wan D; Wang YJ; Yi QY; Guo BH; Liu YJ
Eur J Med Chem; 2018 Feb; 145():302-314. PubMed ID: 29331753
[TBL] [Abstract][Full Text] [Related]
9. Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.
Zheng Y; He L; Zhang DY; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2017 Aug; 46(34):11395-11407. PubMed ID: 28813052
[TBL] [Abstract][Full Text] [Related]
10. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
11. Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.
Yi QY; Zhang WY; He M; Du F; Wang XZ; Wang YJ; Gu YY; Bai L; Liu YJ
J Biol Inorg Chem; 2019 Mar; 24(2):151-169. PubMed ID: 30564887
[TBL] [Abstract][Full Text] [Related]
12. Membrane localized iridium(III) complex induces endoplasmic reticulum stress and mitochondria-mediated apoptosis in human cancer cells.
Cao R; Jia J; Ma X; Zhou M; Fei H
J Med Chem; 2013 May; 56(9):3636-44. PubMed ID: 23594206
[TBL] [Abstract][Full Text] [Related]
13. Histidine-iridium(III) coordination-based peptide luminogenic cyclization and cyclo-RGD peptides for cancer-cell targeting.
Ma X; Jia J; Cao R; Wang X; Fei H
J Am Chem Soc; 2014 Dec; 136(51):17734-7. PubMed ID: 25486120
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a luminescent cyclometalated iridium(III) complex having N,N-diethylamino group that stains acidic intracellular organelles and induces cell death by photoirradiation.
Moromizato S; Hisamatsu Y; Suzuki T; Matsuo Y; Abe R; Aoki S
Inorg Chem; 2012 Dec; 51(23):12697-706. PubMed ID: 23145911
[TBL] [Abstract][Full Text] [Related]
15. Designing new iridium(iii) arene complexes of naphthoquinone derivatives as anticancer agents: a structure-activity relationship study.
Tabrizi L; Chiniforoshan H
Dalton Trans; 2017 Feb; 46(7):2339-2349. PubMed ID: 28138683
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex.
Yi QY; Wan D; Tang B; Wang YJ; Zhang WY; Du F; He M; Liu YJ
Eur J Med Chem; 2018 Feb; 145():338-349. PubMed ID: 29331805
[TBL] [Abstract][Full Text] [Related]
18. Luminescent cyclometalated iridium(III) polypyridine di-2-picolylamine complexes: synthesis, photophysics, electrochemistry, cation binding, cellular internalization, and cytotoxic activity.
Lee PK; Law WH; Liu HW; Lo KK
Inorg Chem; 2011 Sep; 50(17):8570-9. PubMed ID: 21834537
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and photochemical properties of pH responsive tris-cyclometalated iridium(III) complexes that contain a pyridine ring on the 2-phenylpyridine ligand.
Nakagawa A; Hisamatsu Y; Moromizato S; Kohno M; Aoki S
Inorg Chem; 2014 Jan; 53(1):409-22. PubMed ID: 24341415
[TBL] [Abstract][Full Text] [Related]
20. Group 9 organometallic compounds for therapeutic and bioanalytical applications.
Ma DL; Chan DS; Leung CH
Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
